Cargando…

Therapeutic Development and Drugs for the Treatment of COVID-19

SARS-CoV-2/novel coronavirus (2019-nCoV) is a new strain that has recently been confirmed in Wuhan City, Hubei Province of China, and spreads to more than 165 countries of the world including India. The virus infection leads to 245,922 confirmed cases and 10,048 deaths worldwide as of March 20, 2020...

Descripción completa

Detalles Bibliográficos
Autores principales: Maurya, Vimal K., Kumar, Swatantra, Bhatt, Madan L. B., Saxena, Shailendra K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189400/
http://dx.doi.org/10.1007/978-981-15-4814-7_10
_version_ 1783527489325236224
author Maurya, Vimal K.
Kumar, Swatantra
Bhatt, Madan L. B.
Saxena, Shailendra K.
author_facet Maurya, Vimal K.
Kumar, Swatantra
Bhatt, Madan L. B.
Saxena, Shailendra K.
author_sort Maurya, Vimal K.
collection PubMed
description SARS-CoV-2/novel coronavirus (2019-nCoV) is a new strain that has recently been confirmed in Wuhan City, Hubei Province of China, and spreads to more than 165 countries of the world including India. The virus infection leads to 245,922 confirmed cases and 10,048 deaths worldwide as of March 20, 2020. Coronaviruses (CoVs) are lethal zoonotic viruses, highly pathogenic in nature, and responsible for diseases ranging from common cold to severe illness such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) in humans for the past 15 years. Considering the severity of the current and previous outbreaks, no approved antiviral agent or effective vaccines are present for the prevention and treatment of infection during the epidemics. Although, various molecules have been shown to be effective against coronaviruses both in vitro and in vivo, but the antiviral activities of these molecules are not well established in humans. Therefore, this chapter is planned to provide information about available treatment and preventive measures for the coronavirus infections during outbreaks. This chapter also discusses the possible role of supportive therapy, repurposing drugs, and complementary and alternative medicines for the management of coronaviruses including COVID-19.
format Online
Article
Text
id pubmed-7189400
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-71894002020-04-29 Therapeutic Development and Drugs for the Treatment of COVID-19 Maurya, Vimal K. Kumar, Swatantra Bhatt, Madan L. B. Saxena, Shailendra K. Coronavirus Disease 2019 (COVID-19) Article SARS-CoV-2/novel coronavirus (2019-nCoV) is a new strain that has recently been confirmed in Wuhan City, Hubei Province of China, and spreads to more than 165 countries of the world including India. The virus infection leads to 245,922 confirmed cases and 10,048 deaths worldwide as of March 20, 2020. Coronaviruses (CoVs) are lethal zoonotic viruses, highly pathogenic in nature, and responsible for diseases ranging from common cold to severe illness such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) in humans for the past 15 years. Considering the severity of the current and previous outbreaks, no approved antiviral agent or effective vaccines are present for the prevention and treatment of infection during the epidemics. Although, various molecules have been shown to be effective against coronaviruses both in vitro and in vivo, but the antiviral activities of these molecules are not well established in humans. Therefore, this chapter is planned to provide information about available treatment and preventive measures for the coronavirus infections during outbreaks. This chapter also discusses the possible role of supportive therapy, repurposing drugs, and complementary and alternative medicines for the management of coronaviruses including COVID-19. 2020-04-30 /pmc/articles/PMC7189400/ http://dx.doi.org/10.1007/978-981-15-4814-7_10 Text en © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Maurya, Vimal K.
Kumar, Swatantra
Bhatt, Madan L. B.
Saxena, Shailendra K.
Therapeutic Development and Drugs for the Treatment of COVID-19
title Therapeutic Development and Drugs for the Treatment of COVID-19
title_full Therapeutic Development and Drugs for the Treatment of COVID-19
title_fullStr Therapeutic Development and Drugs for the Treatment of COVID-19
title_full_unstemmed Therapeutic Development and Drugs for the Treatment of COVID-19
title_short Therapeutic Development and Drugs for the Treatment of COVID-19
title_sort therapeutic development and drugs for the treatment of covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189400/
http://dx.doi.org/10.1007/978-981-15-4814-7_10
work_keys_str_mv AT mauryavimalk therapeuticdevelopmentanddrugsforthetreatmentofcovid19
AT kumarswatantra therapeuticdevelopmentanddrugsforthetreatmentofcovid19
AT bhattmadanlb therapeuticdevelopmentanddrugsforthetreatmentofcovid19
AT saxenashailendrak therapeuticdevelopmentanddrugsforthetreatmentofcovid19